22.70EUR+3.89%Mkt Cap: 905.59M EURP/E: 3.95Last update: 2026-05-14
Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union. The company deve…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)3.95
P/E (Forward)-55.88
PEG—
P/B7.20
P/S2.83
EV/EBITDA2.07
EV/Revenue1.68
EPS (TTM)5.70
EPS (Forward)-0.40
Cash Flow & Leverage
FCF Yield22.26%
FCF Margin63.04%
Operating CF267.96M EUR
CapEx (TTM)3.63M EUR
Net Debt/EBITDA-1.42
Net Debt-368.30M EUR
Technical
SMA 5021.75 (+4.4%)
SMA 20022.54 (+0.7%)
Beta-0.02
S&P 52W Chg24.23%
Avg Vol (30d)21.34K
Avg Vol (10d)14.96K
Technical Indicators
RSI (14)63.6
MACD0.1798
MACD Signal0.0355
MACD Hist.+0.1444
BB Upper22.52 EUR
BB Middle21.42 EUR
BB Lower20.32 EUR
BB Width10.28%
ATR (14)0.7371 EUR
Vol Ratio (20d)0.54x
52W Range
19.5638% of range27.80
52W High27.80 EUR
52W Low19.56 EUR
Profitability
Gross Margin98.31%
EBITDA Margin81.35%
Profit Margin73.07%
Oper. Margin87.72%
ROE61.43%
ROA52.52%
Revenue Growth310.80%
Earnings Growth300.10%
Balance Sheet
Debt/Equity0.03
Current Ratio7.76
Quick Ratio7.69
Book Value/Sh3.125 EUR
Cash/Share9.414 EUR
Dividends
Fwd Div Rate0.7000 EUR
Trail. Div Rate0.7000 EUR
Div. Yield3.11%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateMay 18, 2026
Pay Date—
Ownership
Shares Out.28.88M
Float10.75M
Insiders62.15%
Institutions9.24%
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)27.67 EUR
Target Range19.00 EUR – 34.00 EUR
# Analysts3
Company
Market Cap905.59M EUR
Enterprise Value538.04M EUR
Revenue (TTM)319.73M EUR
Gross Profit309.02M EUR
Net Income (TTM)229.68M EUR
Revenue/Share7.939 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees214
Last Price22.70 EUR
CountryIT
SectorHealthcare
IndustryBiotechnology
ISINIT0005373789